HiberCell
619 West 54th Street, 8th Floor
New York
NY
10119
United States
Tel: 212.601.2800
Website: http://www.hibercell.com/
Email: contact@HiberCell.com
About HiberCell
Despite significant advances in treatment of primary tumors, metastatic cancer remains a leading cause of solid cancer mortality.1 HiberCell seeks to change that. As “the dormancy company,” we are the first company exclusively focused on therapeutically modulating the biology and mechanisms of tumor dormancy. Toward this goal we are developing first-in-class therapeutics that target dormant disseminated tumor cells (DTCs) from solid and liquid cancers. Our ultimate goal is to prevent or delay the recurrence of cancer.
11 articles with HiberCell
-
BioSpace Movers & Shakers, Oct. 1
10/1/2021
Biopharma companies and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers. -
HiberCell Appoints Jonathan Lanfear as Chief Operating Officer
9/30/2021
HiberCell, a clinical stage biotechnology company developing therapeutics to treat cancer relapse and metastasis, announced the appointment of Jonathan Lanfear as chief operating officer with a focus on leading and driving HiberCell’s emerging global reach.
-
HiberCell Receives Fast Track Designation from FDA for First-in-Human Studies of PERK Inhibitor (PERKi) HC-5404-FUHC-5404-FU PERKi Program is Currently in a Phase 1a Clinical Trial for the Treatment of Solid Tumors
9/8/2021
HiberCell, a clinical stage biotechnology company developing therapeutics to treat cancer relapse and metastasis, announced that the U.S. Food and Drug Administration has granted the company Fast Track designation for HC-5404-FU, an orally administered PERK inhibitor for patients with solid tumors.
-
HiberCell Expands Translational Oncology Toolbox by Acquiring Genuity Science, Inc.
8/16/2021
HiberCell announced today the acquisition of Genuity Science, Inc., a life science technology company that provides world-leading genomics and multi-omic analytics bolstered by an advanced artificial intelligence (AI) and machine learning (ML) platform to illuminate the underlying cause of cancer and other diseases.
-
BioSpace Movers & Shakers, July 2
7/2/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
HiberCell Appoints Mark J. Mulvihill, Ph.D., Chief Scientific OfficerIndustry veteran promoted to oversee discovery of HiberCell’s scientific pipeline
6/29/2021
HiberCell, a biotechnology company developing therapeutics focused on preventing cancer relapse and metastasis, announced the appointment of Mark J. Mulvihill, Ph.D., as Chief Scientific Officer, who brings more than 20 years of experience in drug discovery and development with a focus on small molecule therapies.
-
Money on the Move: May 19-25
5/26/2021
Drug development requires solid funding. Here's who's standing on higher ground this week with fresh investment dollars. -
BioSpace Movers & Shakers. Dec. 4
12/4/2020
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
HiberCell Bolsters Leadership Team with Appointment of Joseph Talamo as Chief Financial Officer and Promotion of Ari Nowacek, M.D., Ph.D., to Chief Business Officer
12/2/2020
HiberCell, a biotechnology company dedicated to overcoming foundational barriers that prevent patients from living longer, cancer-free lives, announced the appointment of Joseph Talamo as chief financial officer and the promotion of Ari Nowacek, M.D., Ph.D., to chief business officer.
-
HiberCell Announces Acquisition of Biothera Pharmaceuticals' Imprime PGG Program
7/7/2020
- Imprime PGG, a novel immune activator, has undergone rigorous Phase II testing for the treatment of metastatic breast cancer - Biothera president and chief scientific officer, Jeremy R. Graff, Ph.D., will assume the role of chief development officer at HiberCell
-
BioSpace is proud to present its NextGen Bio “Class of 2020,” a list of up-and-coming life science companies in North America that launched no earlier than mid-2018.